Exchange Traded Concepts LLC Has $884,000 Stake in Natera, Inc. (NASDAQ:NTRA)

Exchange Traded Concepts LLC lowered its position in Natera, Inc. (NASDAQ:NTRA) by 53.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,587 shares of the medical research company’s stock after selling 6,477 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Natera were worth $884,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc lifted its stake in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Quarry LP lifted its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares during the last quarter. Covestor Ltd boosted its stake in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC increased its holdings in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares during the last quarter. Finally, True Wealth Design LLC bought a new stake in Natera in the 3rd quarter valued at $57,000. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Robert W. Baird upped their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Craig Hallum lifted their target price on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. TD Cowen increased their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Finally, Leerink Partners lifted their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $165.88.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48. Following the sale, the chief executive officer now owns 185,034 shares of the company’s stock, valued at $27,090,827.94. This trade represents a 2.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $126.45, for a total value of $235,955.70. Following the sale, the chief financial officer now owns 68,851 shares in the company, valued at $8,706,208.95. This represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 243,546 shares of company stock valued at $40,338,829 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Stock Up 1.7 %

NASDAQ NTRA opened at $168.08 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a fifty-two week low of $62.96 and a fifty-two week high of $183.00. The stock has a market capitalization of $22.19 billion, a PE ratio of -95.50 and a beta of 1.65. The business has a fifty day moving average price of $166.55 and a two-hundred day moving average price of $137.21.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the previous year, the business posted ($0.95) earnings per share. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. Equities analysts expect that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.